Special Drug Use Investigation of EYLEA for CRVO

Trial Profile

Special Drug Use Investigation of EYLEA for CRVO

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central retinal vein occlusion
  • Focus Adverse reactions
  • Acronyms JPMS-CRVO
  • Sponsors Bayer
  • Most Recent Events

    • 17 Mar 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019 as per ClinicalTrails.gov record.
    • 18 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Nov 2015 Planned End Date changed from 1 Sep 2020 to 1 Nov 2018 as reported by ClinicalTrail.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top